Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
This study explores a new medicine called Diroximel Fumarate (DRF) for people with schizophrenia. Researchers believe a brain chemical called glutathione (GSH) might be lower in schizophrenia and could be a target for new treatments. DRF is already used for another brain condition. This research aims to see if DRF can increase GSH in the brain of people with schizophrenia, using special brain scans. They will also check if any changes in this chemical are linked to the symptoms experienced. Participants will take DRF, and some will be given a dummy pill, to compare the effects. The goal is to see if DRF could be a helpful treatment and to guide future studies.
Överblick
Vad handlar denna studie om?
Schizophrenia is a serious mental health condition that affects about 1 in every 100 people. It can cause symptoms like hearing or seeing things that aren't there (hallucinations), false beliefs (delusions), feeling less motivated, and having trouble thinking clearly. For many, these symptoms don't go away easily, highlighting a need for better treatments.
Scientists are looking into a brain chemical called glutathione (GSH). GSH is like the body's natural antioxidant, protecting brain cells. Evidence suggests that levels of GSH might be different in people with schizophrenia. This study wants to find out if a medicine called Diroximel Fumarate (DRF), which is currently used for a different brain condition (multiple sclerosis), can increase the amount of GSH in the brains of people with schizophrenia. They will use special brain scans, similar to detailed photographs, to measure these changes.
The study also aims to see if any changes in brain GSH are connected to other measurements of brain activity and the symptoms people experience. The results will help researchers understand if DRF could be a promising treatment for schizophrenia and will guide future research into new ways to help people living with this condition.
Viktiga punkter
- This study explores a new potential treatment (DRF) for schizophrenia.
- It investigates how DRF might affect a brain chemical called glutathione (GSH).
- Participation involves taking pills and having regular brain scans (MRI) and other tests.
- The study includes a 'randomised' phase where participants either get DRF or a dummy pill.
- Results will help guide future research into new schizophrenia treatments.
- The study lasts approximately one month for each participant.
Vem kan vara berättigad?
To join this study, you need to be between 18 and 65 years old and have a diagnosis of schizophrenia. It's important that your current antipsychotic medication dose has been stable for at least a month, and your mental health has been stable, without a relapse, for the past two months. You also need to be able to understand the study information and agree to take part.
There are several reasons why someone might not be able to join. These include having certain other serious medical conditions like HIV, cancer, or severe kidney or liver problems. If you are pregnant or breastfeeding, or if you could become pregnant and are not using effective contraception, you cannot take part. Additionally, if you are taking medications that might react badly with DRF, or if you have a high risk of suicide or are misusing substances other than cigarettes, this study might not be suitable for you.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du mellan 18 och 65 år gammal?
- Do you have a diagnosis of schizophrenia?
- Has your current medication dose been stable for at least a month?
- Have you been mentally stable with no relapse in the last 2 months?
- Kan du förstå studien och samtycka till att delta?
- Are you *not* pregnant, breastfeeding, or trying to get pregnant without effective contraception?
Vad innebär deltagande?
If you decide to take part, you'll first take the study drug, Diroximel Fumarate (DRF), for two weeks. The dose will start lower and then increase. After this, a computer will randomly decide whether you continue with DRF or switch to a dummy pill (placebo) for another two weeks. Neither you nor the study team will know which you are taking during this second phase.
Throughout the study, you'll have several appointments. These will include blood tests, questionnaires about your schizophrenia symptoms, measurements of your brain's electrical activity (EEG), and special brain scans (MRI). These assessments will be done at the beginning of the study, after the first two weeks, and again at the end of the second phase. The total duration of your active participation, including medication and assessments, would be about one month.
Potentiella risker och fördelar
Platser (3)
- South London and Maudsley NHS Foundation TrustVerifierat postnummerLondon, Storbritannien· Rekrytering
- Department of Computer Science, Faculty of Engineering Science, University College LondonVerifierat postnummerLondon, Storbritannien· Rekrytering
- School of Psychology, University of birminghamVerifierat postnummerBirmingham, Storbritannien· Rekrytering
Vanliga frågor
What is schizophrenia?
Schizophrenia is a mental health condition that can cause symptoms like seeing or hearing things that aren't there, false beliefs, and trouble with thinking clearly and motivation.
What is glutathione (GSH)?
Glutathione (GSH) is a natural chemical in your brain that acts like an antioxidant, helping to protect your brain cells.
What is Diroximel Fumarate (DRF)?
Diroximel Fumarate (DRF) is a medicine currently used to treat another brain condition called multiple sclerosis. We are investigating if it can help with schizophrenia.
Vad är ett 'sockerpiller' (placebo)?
A dummy pill (placebo) looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the real effects of the medicine.
Will I know if I'm getting the study drug or the dummy pill?
During part of the study, neither you nor the research team will know if you're taking the study drug or the dummy pill. This is standard practice in medical research to ensure fair results.
Hur du får reda på mer
Violeta Perez-Rodriguez, Clinical Research Associate
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.